1-10 of 10
Nicolas Meyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629

Åse Bratland, Jean-Jacques Grob, Eva Munoz Couselo, Laurent Mortier, Ralf Gutzmer, Osama Roshdy, Rene Mendoza Gonzalez, Jacob Schachter, Ana M. Arance Fernandez, Florent Grange, Nicolas Meyer, Abhishek J. Joshi, Salem Billan, Judong Shen, Razvan Cristescu, Michael Nebozhyn, Andrey Loboda, Jason Sparkowski, Burak Gumuscu, Jianda Yuan, Brett Hughes
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT207.
https://doi.org/10.1158/1538-7445.AM2024-CT207
Published: 05 April 2024
View article titled, Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629
Journal Articles

Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma

Reinhard Dummer, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean-Jacques Grob, David C. Portnoy, Celeste Lebbe, Muhammad A. Khattak, Jonathan Cohen, Gil Bar-Sela, Inderjit Mehmi, Ronnie Shapira Frommer, Nicolas Meyer, Yixin Ren, Mizuho Fukunaga-Kalabis, Clemens Krepler, Georgina V. Long
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT002.
https://doi.org/10.1158/1538-7445.AM2023-CT002
Published: 14 April 2023
View article titled, Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
Journal Articles

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Georgina V. Long, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen J. Gogas, Stéphane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Alexander Menzies, Sandra Re, Tuba O. Bas, Veerle de Pril, Daniel Tenney, Hao Tang, Jeffrey S. Weber
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT004.
https://doi.org/10.1158/1538-7445.AM2021-CT004
Published: 01 July 2021
View article titled, Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)
Journal Articles

Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629

Brett G.M. Hughes, Eva Munoz-Couselo, Laurent Mortier, Åse Bratland, Ralf Gutzmer, Osama Roshdy, Rene González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolas Meyer, Abhishek Joshi, Salem Billan, Pingye Zhang, Burak Gumuscu, Ramona F. Swaby, Jean-Jacques Grob
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT006.
https://doi.org/10.1158/1538-7445.AM2021-CT006
Published: 01 July 2021
View article titled, Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629
Journal Articles

Abstract CT170: KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma

Jean-Jacques Grob, Rene Gonzalez Mendoza, Nicole Basset-Seguin, Jacob Schachter, Olga Vornicova, Jessica Bauman, Florent Grange, Nicolas Meyer, Josep Piulats, Pingye (Eric) Zhang, Burak Gumuscu, Ramona Swaby, Brett GM Hughes
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT170.
https://doi.org/10.1158/1538-7445.AM2019-CT170
Published: 01 July 2019
View article titled, Abstract CT170: KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma
Journal Articles

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

Michael Postow, Jason Chesney, Anna Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald Linette, Nicolas Meyer, Jeffrey Giguere, Sanjiv Agarwala, Montaser Shaheen, Marc Ernstoff, David Minor, April Salama, Matthew Taylor, Patrick Ott, Joel Jiang, Christine Horak, Paul Gagnier, Jedd Wolchok, F. Stephen Hodi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT002.
https://doi.org/10.1158/1538-7445.AM2016-CT002
Published: 15 July 2016
View article titled, Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Journal Articles

Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone

F. Stephen Hodi, Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald Linette, Nicolas Meyer, Jeffrey Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April Salama, Matthew H. Taylor, Linda Rollin, Christine Horak, Paul Gagnier, Jedd D. Wolchok
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2860.
https://doi.org/10.1158/1538-7445.AM2015-2860
Published: 01 August 2015
View article titled, Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone
Journal Articles

Abstract 1219: Patient-derived tumor models of resistant metastatic melanoma

Bruno Gomes, Céline ROBICHON, Arnaud Pillon, Jean-Philippe Annereau, Sandrine Pourtau, Jean-Christophe Blanchet, Aline Stennevin, Karim Bedjeguelal, Philippe Rochaix, Ignacio Garrido-Stowhas, Laurence Lamant, Nicolas Meyer, Nicolas Guilbaud, Christian Bailly, Anna Kruczynski
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1219.
https://doi.org/10.1158/1538-7445.AM2014-1219
Published: 01 October 2014
View article titled, Abstract 1219: Patient-derived tumor models of resistant metastatic melanoma
Journal Articles

Abstract 1865: Circulating microRNA expression profile: miR-1246 and miR-185 profile as a novel diagnostic biomarker for melanoma

Virginie Armand-Labit, Nicolas Meyer, Anne Casanova, Stephane Verdun, Marie Bruillard, Gilles Favre, Anne Pradines
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1865.
https://doi.org/10.1158/1538-7445.AM2014-1865
Published: 01 October 2014
View article titled, Abstract 1865: Circulating microRNA expression profile: miR-1246 and miR-185 profile as a novel diagnostic biomarker for melanoma
Journal Articles

Targeting the Nuclear Factor-κB Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy

Carole Sourbier, Sabrina Danilin, Véronique Lindner, Jacques Steger, Sylvie Rothhut, Nicolas Meyer, Didier Jacqmin, Jean-Jacques Helwig, Hervé Lang, Thierry Massfelder
Journal: Cancer Research
Cancer Res (2007) 67 (24): 11668–11676.
https://doi.org/10.1158/0008-5472.CAN-07-0632
Published: 18 December 2007
View article titled, Targeting the Nuclear Factor-κB Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy
Open the PDF for Targeting the Nuclear Factor-κB Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy in another window
Includes: Supplementary data